Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|96|2|192-205

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.2, 2014-08, pp. : 192-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

So Far So Good

By  

Respiration, Vol. 66, Iss. 1, 1999-02 ,pp. : 1-1

Karger

Access to resources Recommend Favorite

Pediatric solid organ transplantation and end stage disease: A slow journey towards understanding neurocognitive outcomes and their ramifications for clinical care

By  

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 2, 2015-03 ,pp. : 136-138

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tapentadol ‐ the evidence so far

By  

ANAESTHESIA, Vol. 70, Iss. 5, 2015-05 ,pp. : 518-522

John Wiley & Sons Inc

Access to resources Recommend Favorite

Associations of impaired glucose metabolism and dyslipidemia with cardiovascular diseases: what have we learned from Japanese cohort studies for individualized prevention and treatment?

By Kokubo Yoshihiro  

The EPMA Journal, Vol. 2, Iss. 1, 2011-03 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite

APOC at mid-point: so far so good

By Sékétéli A.  

Annals of Tropical Medicine and Parasitology, Vol. 96, Iss. 1, 2002-03 ,pp. : 3-4

Maney Publishing

Access to resources Recommend Favorite